Navigation Links
Diabetes drug class linked to vision-threatening complication
Date:4/2/2009

Philadelphia, PA, 2 April 2009 Treatment with the glitazone class of diabetes drugs leads to a "modest" increase in the risk of diabetic macular edema (DME)a common complication that can lead to vision loss, reports a study in the April issue of the American Journal of Ophthalmology (http://www.elsevier.com/locate/ajo), published by Elsevier.

Using a database of about 170,000 patients with diabetes, Drs. Donald S. Fong and Richard Contreras of Southern California Permanente Medical Group analyzed the link between glitazones and the development of DME. Diabetic macular edema is a common diabetes complication, with swelling and fluid build-up in the retina leading to progressive visual loss.

The researchers identified 996 patients who were diagnosed with DME during 2006. Overall, patients who took glitazones were 2.6 times more likely to develop DME than patients not taking these drugs. Even after further adjustment for other factors, DME risk remained 60 percent higher for glitazone users.

Previous studies have linked glitazones to problems related to fluid retention and edema (swelling), including heart failure. Fluid retention from heart failure or other diseases can worsen DME. Most of the glitazone users in the study were taking pioglitazone (Actos). Other studies have linked rosiglitazone (Avandia)the only other approved glitazone drugto a possible increase in the risk of myocardial infarction.

Although the study is not the first to suggest a link, it provides confirmation in a very large sample of diabetic patients that glitazones are "modestly associated" with DME. Drs. Fong and Contreras concluded, "When treating patients with DME, ophthalmologists should consider the role of the glitazone class of drugs."

"Ocular complications are an overlooked safety issue of systemic drugs," commented Dr. Thomas J. Liesegang, Editor-in-Chief of AJO, "Safety is as important as the efficacy of a drug. However, long term safety is not currently monitored because the approval process is based on smaller, shorter term clinical trials. Safety necessarily requires monitoring of treatment in larger groups of people over longer periods of time. This monitoring is often neglected and should be required of all therapies."


'/>"/>

Contact: Maureen Hunter
m.hunter@elsevier.com
215-239-3671
Elsevier
Source:Eurekalert

Related medicine news :

1. Lack of Awareness of Eye Health Risk Associated with Diabetes Poses Blinding Threat to Millions
2. Anthem Blue Cross and Blue Shield, Eli Lilly and Company Establish Coalition to Help Improve the Health of Indiana Residents with Diabetes
3. Blue Cross and Blue Shield of Illinois Teams with Chicago Bears Coach Lovie Smith in Diabetes Awareness Drive
4. Survey Reveals Honolulu Residents Perceive Financial Challenges as Main Barrier in Properly Managing Their Type 2 Diabetes
5. American Diabetes Association Alert(R) Day Video - Do You Have Diabetes?
6. Many Americans Fear Being Diagnosed With Diabetes
7. Supermodel Izabel Goulart Partners With Diabetes Research Institute Foundation as International Ambassador
8. City Councilors Nancy White, RN, Charles Jones, and Ed DeFore Launch Medicare Diabetes Screening Project in Macon
9. Home Care Delivered, Inc. Recognizes 21st Annual American Diabetes Alert Day
10. South Asians with diabetes more likely to lose their eyesight earlier than white Europeans
11. Control or Prevent Diabetes Through Healthier Habits, Pennsylvania Health Secretary Urges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... PR ... an upcoming case studies guidebook. This guidebook offers an excellent branding and exposure ... include articles, case studies and how-to’s that fall into the following categories:, ...
(Date:6/27/2017)... ... , ... Dr. Richard Amato, a respected periodontist in Monroe, CT, ... Implant Center of Connecticut. As part of the renovation, the cutting-edge practice added two ... to improve patient comfort while making it possible for Dr. Amato to provide even ...
(Date:6/27/2017)... North Hollywood, CA (PRWEB) , ... June 27, ... ... on orthodontic treatments . Orthodontics is a dental specialty that focuses on ... other appliances. Benefits include improved aesthetics and function. , North Hollywood ...
(Date:6/26/2017)... ... June 26, 2017 , ... Torrance dentist, Dr. Robert ... be one of the most noticeable aspects of a person’s appearance. A healthy, radiant ... is born with beautiful, balanced teeth, everyone can have the smile of their dreams ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for Advanced ... hiring of Richard Robinson as chief operating officer (COO). In this role, Robinson ... proven track record of simplifying business processes and developing growth strategies to increase ...
Breaking Medicine News(10 mins):
(Date:6/20/2017)... HILLS, Calif. , June 20, 2017 SkylineDx ... the use of MMprofiler with SKY92, the company,s prognostic ... In a poster presentation at the 22 nd ... Madrid, Spain , SkylineDx researchers will demonstrate ... patients. In a separate e-poster presentation ...
(Date:6/14/2017)... HAMPTON, Va. , June 14, 2017  ivWatch ... safety and effectiveness of intravenous (IV) therapy, is pleased ... in the category of Nonsurgical Hospital Supplies and Equipment ... premier awards program for the medtech industry. The award ... at the Jacob K. Javits Center in ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology: